First humans test new eczema shot in early safety trial
NCT ID NCT06920693
Summary
This is the first-ever study in humans of a new drug called GB-7624, which is being developed for atopic dermatitis (eczema). The main goal is to check if the drug is safe and how the body processes it. The study will enroll 40 healthy adult volunteers to receive either the drug or a placebo as an injection under the skin, testing single and multiple doses.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Generate Biomedicines Clinical Site
Herston, Queensland, 4007, Australia
Conditions
Explore the condition pages connected to this study.